Kiromic Biopharma, Inc.
7707 Fannin, Suite 140
Houston, TX 77054
| May 17, 2023 |
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Timothy Buchmiller
Re: | Kiromic Biopharma, Inc. |
| Registration Statement on Form S-1 |
| May 15, 2023 |
| File No. 333-271950 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Kiromic Biopharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Friday, May 19, 2023, or as soon thereafter as possible.
Please notify Jeff Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
| KIROMIC BIOPHARMA, INC. | |
|
| |
| By: | /s/ Pietro Bersani |
| Name: | Pietro Bersani |
| Title: | Chief Executive Officer |
| -1- | |
| | |